Advanced Breast Cancer
Conditions
Keywords
BMI, CDK4/6 Inhibitors
Brief summary
Exploring the Impact of body mass index on the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in advanced breast cancer.
Detailed description
Body mass index (BMI) is strongly associated with the development and progression of breast cancer. Despite the widespread use of cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy (ET) in hormone receptor (HR)-positive advanced breast cancer, the effect of BMI on therapeutic outcomes remains poorly understood. Here, we present real-world evidence to substantiate the association between BMI and CDK4/6 inhibitors efficacy and safety.
Interventions
DRUGImpact of BMI on CDK4/6 Inhibitors Efficacy and Safety
Patients aged ≥18 years with advanced HR-positive breast cancer who received CDK4/6 inhibitors at six hospitals in China were included in this study.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* 18 years of age and above; * Women of any menstrual status; * Histologically confirmed recurrent or metastatic breast cancer, including patients initially diagnosed as stage IV or locally advanced inoperable; * Patients with histological pathology that is clearly HR-positive/HER2-negative breast cancer, or if there is metastatic pathology, the histological pathology of the metastatic foci shall prevail. (Those with ER intensity \>1% cellular nuclear staining) * Patients have at least 3 more fully documented medical records at the enrolled centre, including at least 1 inpatient record.
Exclusion criteria
* CDK4/6 inhibitors as neoadjuvant or adjuvant therapy; * Significantly missing diagnostic and treatment data from patients' medical records; * Participation in other clinical trials before and during the data collection period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Progression-free survival estimated using Kaplan-Meier methods is defined as the time from the date of informed consent to the earlier of death or disease progression. Patients alive without disease progression are censored at the date of last disease evaluation. Progressive disease (PD) based on RECIST 1.1 is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Equivocal progression of non-target lesions also qualifies as PD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | It is defined as the time from the start of treatment to death for any reason, whichever came first, assessed up to 100 months | It is defined as the time from the start of treatment to death for any reason. |
| Objective Response Rate (ORR) | From date of observation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | The overall response rate is defined as the percentage of patients with a best overall response of CR or PR relative to the appropriate analysis set |
| The Number of Participants Who Experienced Adverse Events | From date of observation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Safety will be assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events). |
Countries
China
Outcome results
None listed